Einar Stensvold1,2,3, Tor Åge Myklebust4,5, Johan Cappelen6, Bernt J Due-Tønnessen7, Paulina Due-Tønnessen8, Aleksandra Kepka9, Tom Børge Johannesen4, Bård Krossnes10, Tryggve Lundar7, Snezana Maric11, Hrvoje Miletic12, Viggo Moholdt13, Kristin Smistad Myrmel14, Terje Nordberg15, Jana Rydland13, Tore Stokland16, Kristin Solem17, Ole Solheim6, Ingrid Torsvik18, Gry C Wikran19, Bernward Zeller3,20, Finn Wesenberg3,20, Anne Grete Bechensteen3, Petter Brandal21,22,23. 1. The Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 2. Department of Pediatric Research, Oslo University Hospital, Oslo, Norway. 3. Department of Paediatric Medicine, Oslo University Hospital, Oslo, Norway. 4. Department of Registration, Cancer Registry of Norway, Oslo, Norway. 5. Department of Research and Innovation, Møre and Romsdal Hospital Trust, Ålesund, Norway. 6. Department of Neurosurgery, St Olavs Hospital, Trondheim, Norway. 7. Department of Neurosurgery, Oslo University Hospital, Oslo, Norway. 8. Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway. 9. Department of Pathology, St Olavs Hospital, Trondheim, Norway. 10. Department of Pathology, Oslo University Hospital, Oslo, Norway. 11. Department of Radiology, Haukeland University Hospital, Bergen, Norway. 12. Department of Pathology, Haukeland University Hospital, Bergen, Norway. 13. Department of Radiology and Nuclear Medicine, St Olavs Hospital, Trondheim, Norway. 14. Department of Pathology, University Hospital of North Norway, Tromsø, Norway. 15. Department of Oncology, Haukeland University Hospital, Bergen, Norway. 16. Department of Pediatrics, University Hospital of North Norway, Tromsø, Norway. 17. Department of Pediatrics, St Olavs Hospital, Trondheim, Norway. 18. Department of Pediatrics, Haukeland University Hospital, Bergen, Norway. 19. Department of Radiology and Nuclear Medicine, University Hospital of North Norway, Tromsø, Norway. 20. Norwegian National Advisory Unit on Solid Tumours in children (KSSB), Oslo University Hospital, Oslo, Norway. 21. Department of Oncology, Oslo University Hospital, Oslo, Norway. 22. Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway. 23. Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Abstract
BACKGROUND: A previous study based on Norwegian Cancer Registry data suggested regional differences in overall survival (OS) after treatment for medulloblastoma (MB) and supratentorial primitive neuroectodermal tumor (CNS-PNET) in Norway. The purpose of the present study was to confirm in an extended cohort whether there were regional differences in outcome or not, and if so try to identify possible explanations. MATERIAL AND METHODS: Data from patients aged 0-20 years diagnosed with and treated for MB/CNS-PNET at all four university hospitals in Norway from 1974 to 2013 were collected and compared. RESULTS: Of 266 identified patients, 251 fulfilled inclusion criteria. MB was diagnosed in 200 and CNS-PNET in 51 patients. Five-year OS and event-free survival (EFS) were 59% and 52%, respectively. There was a significant difference in five-year OS and EFS between MB and CNS-PNET patients; 62% versus 47% (P = 0.007) and 57% versus 35% (P < 0.001). In multivariable analysis, two factors were found to significantly contribute to improved five-year OS and EFS, whereas one factor contributed to improved five-year OS only. Gross total resection (GTR) versus non-GTR (hazard ratio [HR] 0.53, P = 0.003; HR 0.46, P < 0.001) and cerebrospinal irradiation (CSI) versus non-CSI (HR 0.24, P < 0.001; HR 0.28, P < 0.001) for both, and treatment outside Oslo University Hospital for OS only (HR 0.64, P = 0.048). CONCLUSION: Survival was comparable with data from other population-based studies, and the importance of GTR and CSI was confirmed. The cause for regional survival differences could not be identified.
BACKGROUND: A previous study based on Norwegian Cancer Registry data suggested regional differences in overall survival (OS) after treatment for medulloblastoma (MB) and supratentorial primitive neuroectodermal tumor (CNS-PNET) in Norway. The purpose of the present study was to confirm in an extended cohort whether there were regional differences in outcome or not, and if so try to identify possible explanations. MATERIAL AND METHODS: Data from patients aged 0-20 years diagnosed with and treated for MB/CNS-PNET at all four university hospitals in Norway from 1974 to 2013 were collected and compared. RESULTS: Of 266 identified patients, 251 fulfilled inclusion criteria. MB was diagnosed in 200 and CNS-PNET in 51 patients. Five-year OS and event-free survival (EFS) were 59% and 52%, respectively. There was a significant difference in five-year OS and EFS between MB and CNS-PNET patients; 62% versus 47% (P = 0.007) and 57% versus 35% (P < 0.001). In multivariable analysis, two factors were found to significantly contribute to improved five-year OS and EFS, whereas one factor contributed to improved five-year OS only. Gross total resection (GTR) versus non-GTR (hazard ratio [HR] 0.53, P = 0.003; HR 0.46, P < 0.001) and cerebrospinal irradiation (CSI) versus non-CSI (HR 0.24, P < 0.001; HR 0.28, P < 0.001) for both, and treatment outside Oslo University Hospital for OS only (HR 0.64, P = 0.048). CONCLUSION: Survival was comparable with data from other population-based studies, and the importance of GTR and CSI was confirmed. The cause for regional survival differences could not be identified.
Authors: Paula Sedano; Carmen González-San Segundo; Lourdes De Ingunza; Pedro Cuesta-Álvaro; Marta Pérez-Somarriba; Francisco Diaz-Gutiérrez; Carmen Garrido Colino; Alvaro Lassaletta Journal: Eur J Pediatr Date: 2020-06-21 Impact factor: 3.183
Authors: Wan-Shui Wu; Jing-Jing Liu; Yan-Ling Sun; Si-Qi Ren; Xiao-Guang Qiu; Shu-Xu DU; Chun-De Li; Li-Ming Sun Journal: Zhongguo Dang Dai Er Ke Za Zhi Date: 2020-06